TW201622721A - Ｓ１ｐ調節劑之立即釋放劑量療法 - Google Patents

Ｓ１ｐ調節劑之立即釋放劑量療法 Download PDF

Info

Publication number
TW201622721A
TW201622721A TW104111330A TW104111330A TW201622721A TW 201622721 A TW201622721 A TW 201622721A TW 104111330 A TW104111330 A TW 104111330A TW 104111330 A TW104111330 A TW 104111330A TW 201622721 A TW201622721 A TW 201622721A
Authority
TW
Taiwan
Prior art keywords
day
dosage form
patient
treatment
immediate release
Prior art date
Application number
TW104111330A
Other languages
English (en)
Chinese (zh)
Inventor
菲利普 米契爾 蕾恩 波洛特
法蘭克 道可
艾力克 勒崗紐斯
艾梅瑞克 瑞諾德
艾利克 沃史托
Original Assignee
諾華公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52988364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW201622721(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 諾華公司 filed Critical 諾華公司
Publication of TW201622721A publication Critical patent/TW201622721A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW104111330A 2014-04-10 2015-04-08 Ｓ１ｐ調節劑之立即釋放劑量療法 TW201622721A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461977816P 2014-04-10 2014-04-10

Publications (1)

Publication Number Publication Date
TW201622721A true TW201622721A (zh) 2016-07-01

Family

ID=52988364

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104111330A TW201622721A (zh) 2014-04-10 2015-04-08 Ｓ１ｐ調節劑之立即釋放劑量療法

Country Status (16)

Country Link
US (4) US20170027907A1 (enExample)
EP (3) EP3129020A1 (enExample)
JP (1) JP6674903B2 (enExample)
KR (2) KR20220156981A (enExample)
CN (2) CN106456552A (enExample)
AU (2) AU2015246036A1 (enExample)
CA (1) CA2943598C (enExample)
CL (1) CL2016002562A1 (enExample)
IL (2) IL305337A (enExample)
MX (1) MX2016013245A (enExample)
PH (1) PH12016501965A1 (enExample)
RU (2) RU2020107732A (enExample)
SG (1) SG11201607894RA (enExample)
TW (1) TW201622721A (enExample)
WO (1) WO2015155709A1 (enExample)
ZA (1) ZA201606519B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (enExample) 2014-01-24 2018-02-24
TW201622721A (zh) * 2014-04-10 2016-07-01 諾華公司 Ｓ１ｐ調節劑之立即釋放劑量療法
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
EP3687530A1 (en) * 2017-09-29 2020-08-05 Novartis AG Dosing regimen of siponimod
WO2019064217A1 (en) * 2017-09-29 2019-04-04 Novartis Ag DOSAGE DIAGRAM OF SIPONIMOD
HRP20250115T1 (hr) * 2018-03-01 2025-05-23 Astrazeneca Ab Farmaceutski pripravci koji sadrže (2s)-{(1s)-1-cijano-2-[4-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-5-il)fenil]etil} -1,4-oksazepan-2-karboksamid
CA3106269A1 (en) 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
CN109908095A (zh) * 2019-04-08 2019-06-21 肇庆学院 一种西尼莫德片剂及制备方法
MX2022005014A (es) 2019-10-31 2022-05-16 Idorsia Pharmaceuticals Ltd Combinacion de un antagonista de cxcr7 con un modulador del receptor s1p1.
US11135197B2 (en) 2020-02-07 2021-10-05 Argentum Pharmaceuticals Llc Dosage regimen of an S1P receptor modulator
EP4646265A1 (en) 2023-01-06 2025-11-12 Insmed Incorporated Novel, reversible dpp1 inhibitors and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160064245A (ko) * 2008-12-18 2016-06-07 노파르티스 아게 1-［4-［1-(4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노)-에틸］-2-에틸-벤질］-아제티딘-3-카르복실산의 헤미푸마레이트 염
DK2379069T3 (en) * 2008-12-22 2015-06-08 Novartis Ag Dosage Plan for an S1P receptor agonist
LT3453387T (lt) * 2008-12-22 2020-08-25 Novartis Ag S1p receptoriaus antagonisto dozavimo režimas
SG178987A1 (en) * 2009-09-29 2012-04-27 Novartis Ag Dosage regimen of an s1p receptor modulator
HRP20191842T1 (hr) * 2011-01-07 2019-12-27 Novartis Ag Formulacije imunosupresiva
WO2012095853A1 (en) 2011-01-10 2012-07-19 Novartis Pharma Ag Modified release formulations comprising sip receptor modulators
CN103889408A (zh) * 2011-10-21 2014-06-25 诺华股份有限公司 S1p受体调节剂或激动剂的剂量方案
TW201622721A (zh) * 2014-04-10 2016-07-01 諾華公司 Ｓ１ｐ調節劑之立即釋放劑量療法

Also Published As

Publication number Publication date
IL305337A (en) 2023-10-01
EP3129020A1 (en) 2017-02-15
AU2020203107B2 (en) 2021-10-21
JP2017510607A (ja) 2017-04-13
CA2943598C (en) 2023-03-07
CA2943598A1 (en) 2015-10-15
AU2015246036A1 (en) 2016-10-13
US20220016076A1 (en) 2022-01-20
SG11201607894RA (en) 2016-10-28
JP6674903B2 (ja) 2020-04-01
EP4074312A1 (en) 2022-10-19
PH12016501965A1 (en) 2017-01-09
US20170027907A1 (en) 2017-02-02
KR20220156981A (ko) 2022-11-28
IL247986A0 (en) 2016-11-30
CL2016002562A1 (es) 2017-07-28
RU2715734C2 (ru) 2020-03-03
CN116650467A (zh) 2023-08-29
KR20160141841A (ko) 2016-12-09
RU2016143979A3 (enExample) 2018-11-12
WO2015155709A1 (en) 2015-10-15
RU2020107732A (ru) 2020-03-30
EP3831378A1 (en) 2021-06-09
ZA201606519B (en) 2017-11-29
CN106456552A (zh) 2017-02-22
MX2016013245A (es) 2017-01-16
US20250041266A1 (en) 2025-02-06
US20190054065A1 (en) 2019-02-21
AU2020203107A1 (en) 2020-05-28
RU2016143979A (ru) 2018-05-14

Similar Documents

Publication Publication Date Title
US20250041266A1 (en) S1p modulator immediate release dosage regimen
JP2003529563A (ja) ビュープロピオン代謝産物並びにその合成および使用方法
AU2018329202B2 (en) Methods for making and using endoxifen
JP7542121B2 (ja) 神経原性起立性低血圧の処置に使用するための化合物
CN113490499A (zh) 用作治疗癌症的活性剂的cdk9抑制剂及其多晶型物
US11944602B2 (en) Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
JP7539898B2 (ja) オピオイド鎮痛耐性を治療するためのｍＧｌｕＲ５アンタゴニストの使用
US20080206331A1 (en) Tablet comprising efletirizine and pseudoephedrine
JP2019529502A (ja) アルツハイマー病及びパーキンソン病を処置するための組成物及び方法
HK40053433A (en) Siponimod immediate release dosage regimen for treating autoimmune diseases
HK40081576A (en) Siponimod immediate release dosage regimen for treating autoimmune diseases
TW200920348A (en) Combination of picotamide with nafronyl
WO2005007145A1 (en) Pharmaceutical product comprising a beta-2 adrenoceptor agonist and an antihistamine
TW202527911A (zh) 用於治療猝睡症的化合物
JPWO2021245280A5 (enExample)
TW202237084A (zh) 修飾釋放調配物及其用途
JP2023527488A (ja) ノルアドレナリン作動性および特異的セロトニン作動性抗不安薬および抗うつ薬、その生産および使用のための方法
JP2016533323A5 (enExample)
JPH08157368A (ja) 脳浮腫治療剤